Dr. Aiping Mao got her PhD degree in Cell Biology from Wuhan University and had worked as a postdoc for Immunology in University of Chicago. Since Oct 2017, Dr. Mao joined Berry Genomics, a Chinese company committed to the comprehensive transformation of genetic testing technologies including long-read sequencing into clinical application, focusing on reproductive health, genetic disease testing. Dr. Mao leads the R&D and Clinical Research teams, is well-known for her pioneering work in developing a serial of long-read sequencing-based assays for complicated monogenic diseases like thalassemia, CAH, SMA, and FXS etc, and applying these assays in large-scale clinical application.